Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT03591965 Terminated - Clinical trials for Hepatocellular Carcinoma

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Start date: August 7, 2018
Phase: Phase 2
Study type: Interventional

This is an Asian multi-regional clinical trial (MRCT) in which ATG-008 will be administered orally to hepatitis B positive (HBV+) HCC subjects who have received at least one prior line of systemic therapy. It is designed as an open-label phase 2 trial evaluating the pharmacokinetics (PK), safety, tolerability and efficacy of oral ATG-008 administered daily until the radiologic disease progression (according to RECIST 1.1) or intolerable toxicity.

NCT ID: NCT03582618 Terminated - Clinical trials for Hepatocellular Carcinoma

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Start date: July 12, 2018
Phase: Phase 2
Study type: Interventional

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.

NCT ID: NCT03511222 Terminated - Clinical trials for Hepatocellular Carcinoma

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Start date: September 11, 2018
Phase: Phase 1
Study type: Interventional

The investigators hypothesize that vorolanib in combination with checkpoint inhibitors (pembrolizumab for gastric/gastroesophageal (GE) junction cancers and nivolumab for hepatocellular carcinoma (HCC)) may improve immunotherapy efficacy by overcoming treatment resistance of checkpoint inhibitors in gastrointestinal (GI) cancers.

NCT ID: NCT03480152 Terminated - Melanoma Clinical Trials

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Start date: May 18, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. In this study, researchers will make a treatment called a messenger ribonucleic acid (mRNA) vaccine. The vaccine might cause certain tumors to shrink. Objective: To see if the mRNA vaccine is safe and can cause metastatic melanoma or epithelial tumors to shrink. Eligibility: People 18-70 years old with metastatic melanoma or epithelial cancer Design: Participants will be screened under protocol 99-C-0128. Participants will provide samples under protocol 03-C-0277: Participants will provide a piece of their tumor from a previous surgery or biopsy. Participants will have leukapheresis: Blood is removed through a needle in one arm and circulated through a machine that takes out the white blood cells. The blood is then returned through a needle in the other arm. Participants will have many tests: Scans and x-rays Heart and lung function tests Blood and urine tests Participants will receive the mRNA vaccine every 2 weeks for up to 8 weeks. They will get the vaccine as an injection into the upper arm or thigh. They may receive a second course of vaccines if the study doctor determines it is needed. Participants will have follow-up visits approximately 2 weeks after their final vaccine, then 1 month later, then every 1-2 months for the first year, and then once a year for up to 5 years. Each visit may take up to 2 days and include: Physical exam Blood tests Scans Leukapheresis at the first visit

NCT ID: NCT03433703 Terminated - Clinical trials for Carcinoma, Hepatocellular

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Start date: April 26, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma (uHCC) participants.

NCT ID: NCT03402607 Terminated - Clinical trials for Hepatocellular Carcinoma

Trial Comparing PLA to HIGRT (PROVE-HCC)

PROVE-HCC
Start date: August 8, 2018
Phase: N/A
Study type: Interventional

This phase II, randomized trial compare Quality of Life for patients with Hepatocellular Carcinoma (HCC) who are not surgical candidates or decline surgery and are treated with Percutaneous Local Ablation (PLA) or Hypofractionated Image-Guided Radiation Therapy (HIGRT).

NCT ID: NCT03382886 Terminated - Clinical trials for Hepatocellular Carcinoma

Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma

NUANCE
Start date: April 11, 2018
Phase: Phase 1
Study type: Interventional

This is an open label, phase I study to test for maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of the combination of nivolumab and bevacizumab. The study will use a 3+3 phase I study design using a fixed dose of nivolumab (240mg) and escalating doses of bevacizumab (1-10mg).

NCT ID: NCT03349255 Terminated - Clinical trials for Hepatocellular Carcinoma

Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

Start date: October 6, 2017
Phase: Phase 1
Study type: Interventional

Clinical study to evaluate safety and pharmacokinetics (primary objectives) and efficacy (secondary objective) of ET1402L1-CART-cells in patients with AFP+ HCC

NCT ID: NCT03318562 Terminated - Clinical trials for Hepatocellular Carcinoma

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Start date: November 21, 2017
Phase: Phase 2
Study type: Interventional

This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.

NCT ID: NCT03303469 Terminated - Clinical trials for Hepatocellular Carcinoma

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Start date: October 30, 2017
Phase: Phase 2
Study type: Interventional

[18F] FMISO Positron Emission Tomography (PET) to determine hypoxia in patients with HCC treated with TACE.